๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
NCT06335355Non-squamous Non-small Cell Lung Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3
401
Jinan
2024-03
Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
NCT06228963MALT Lymphoma of Stomach, Helicobacter Pylori Infection
Fudan University
Phase 2
160
Shanghai
2024-03
Recruiting
The Therapeutic Effect of Betaine in Syringomyelia
NCT06308367Syringomyelia
Xuanwu Hospital, Beijing
Phase 2
30
Beijing
2024-03
Recruiting
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
NCT06313463Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
375
Guangzhou
2024-03
Not yet open
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
NCT06310473Gastric Cancer, Esophagogastric Junction Cancer
Nanfang Hospital, Southern Medical University
Phase 2
30
Guangzhou
2024-03
Recruiting
The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery
NCT06425874Breast Cancer, Surgery, Quality of Life
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1,000
Guangzhou
2024-02-29
Recruiting
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
NCT06131450Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
138
Beijing
2024-02-29
Recruiting
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
NCT06231381Generalized Pustular Psoriasis (GPP)
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 2
33
Beijing, Shanghai
2024-02-29
Recruiting
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
NCT07236203Large B-Cell Lymphoma
Fudan University
Observational
80
Shanghai
2024-02-29
Recruiting
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
NCT06208137Transplant-Related Disorder
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
456
Tianjin
2024-02-29
Active, closed
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
NCT06957379HR+/HER2- Advanced/Metastatic Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
78
Beijing
2024-02-29
Recruiting
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure๏ผšPhase I/II
NCT06195189Non Small Cell Lung Cancer
Sichuan University
Phase 1/2
40
Chengdu
2024-02-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
NCT06775405Respiratory Synctial Virus Infections
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Sanya, Shanghai, Shenyang
2024-02-29
Recruiting
A Clinical Study of AK0610
NCT06996704Healthy Volunteer Study
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 1
136
Jinan
2024-02-29
Recruiting
Non-invasive Tools for PSVD Diagnosis
NCT06500403Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases
Nanfang Hospital, Southern Medical University
Observational
1,000
Guangzhou
2024-02-28
Active, closed
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
NCT04556253MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Peking University
Phase 2
47
Beijing
2024-02-28
Recruiting
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05935215Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals
Phase 3
50
Nanjing, Beijing, Shanghai
2024-02-28
Recruiting
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
NCT06252298Relapsed or Refractory Hematologic Malignancies
Sinocelltech Ltd.
Phase 1
74
Beijing
2024-02-28
Recruiting
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
524
Shanghai
2024-02-28
Recruiting
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
NCT06329973Metastatic Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 1/2
70
Zhengzhou
2024-02-28
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Recruiting
Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment
NCT05926700Soft Tissue Sarcoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2024-02-28
Recruiting
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone๏ผˆGnRH๏ผ‰Antagonist Protocol in Women Undergoing IVF
NCT06023602Infertility
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Not applicable
1,338
Xi'an
2024-02-27
Recruiting
A Study of HC006 in Subjects With Advanced Solid Tumors
NCT06304571Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
Daiichi Sankyo
Phase 2/3
860
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai
2024-02-27
Recruiting
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT06296706Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
630
Shijiazhuang
2024-02-27
Active, closed
The Effect of Oral Probiotics on Allergic Rhinitis Symptoms and the Quality of Life
NCT07532837Allergic Rhinitis
Glac Biotech Co., Ltd
Not applicable
225
2024-02-26
Active, closed
A Study of RAY1225 in Participants With Type 2 Diabetes
NCT06254274T2DM (Type 2 Diabetes Mellitus)
Guangdong Raynovent Biotech Co., Ltd
Phase 2
210
Beijingcun
2024-02-26
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Recruiting
The Effect of LIPUS on the Maturation of Newly Constructed Autogenous AVF
NCT06249373Uremia; Chronic
Suzhou Municipal Hospital
Not applicable
300
Suzhou
2024-02-26
Recruiting
Study of Natural Course Progression of Diabetic Retinopathy
NCT06269419Biomarkers of Diabetic Retinopathy
Jie Li
Observational
200
Chengdu
2024-02-25
Not yet open
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
NCT06289959Lymphoma, Large B-Cell, Diffuse
Second Affiliated Hospital of Soochow University
Not applicable
30
Suzhou
2024-02-25
Recruiting
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
NCT06292650Retinitis Pigmentosa
Zhongmou Therapeutics
Phase EARLY_PHASE1
12
Beijing
2024-02-25
Recruiting
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Hefei, Hangzhou, Wenzhou, Beijing
2024-02-23
Recruiting
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06071013Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
China Medical University Hospital
Phase 1/2
20
2024-02-23
Recruiting
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
NCT06293014Colorectal Cancer
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2024-02-23
Recruiting
Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)
NCT06009315Acute Ischemic Stroke
Beijing Tiantan Hospital
Observational
949
Beijing
2024-02-23
Recruiting
Clinical Study of PEG Bowel Preparation in Appendectomy Patients
NCT07478029Appendicitis, Appendicitis Acute
Huaping Xie
Observational
10
Wuhan
2024-02-23
Recruiting
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
NCT06254521Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2024-02-22
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
NCT06271837Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NCT06232096Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
154
Beijing
2024-02-22
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Recruiting
Effect of Metformin on Healthy Live Birth in Women With Prediabetes
NCT06064669Metformin, Prediabetes, In-Vitro Fertilization
Shandong University
Not applicable
988
Jinan
2024-02-22
Recruiting
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
NCT06265545AML, Refractory, Relapsed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
458
Tianjin
2024-02-22
Recruiting
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
NCT06225804Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
Clinical Outcomes of Patients With Coronary Artery Disease
NCT06216847Coronary Heart Disease (CHD)
Shenyang Northern Hospital
Observational
10,000
Shenyang
2024-02-21
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Recruiting
A Study of RAY1225 in Participants With Obesity
NCT06254261Obesity
Guangdong Raynovent Biotech Co., Ltd
Phase 2
270
Beijingcun
2024-02-21
Recruiting
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
NCT06277154Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
HRYZ Biotech Co.
Phase 2
148
Guangzhou
2024-02-21
Active, closed
Prospective Cohort Study of Panvascular Disease
NCT06295861ASCVD
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50,000
Hangzhou
2024-02-21
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Recruiting
Efficacy of Bioceramic Materials for Bone Defects Repair
NCT06249906Bone Lesion, Cartilage Degeneration, Osteo Arthritis Knee, Bone Fracture
Nanjing First Hospital, Nanjing Medical University
Not applicable
10
Nanjing
2024-02-20
Recruiting
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
NCT06222879Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
350
Changsha
2024-02-20
Recruiting
Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
NCT06207552Fabry Disease
Children's Hospital of Fudan University
Phase EARLY_PHASE1
6
Shanghai
2024-02-20
Recruiting
Neoadjuvant Immunochemotherapy for LAOSCC
NCT06258811Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Lai-ping Zhong
Phase 3
134
Shanghai
2024-02-20
Recruiting
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
NCT06210490Upper Urinary Tract Urothelial Carcinoma
Peking University First Hospital
Phase 2
60
Beijing
2024-02-20
Recruiting
A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab๏ผˆAK104๏ผ‰ for Newly Diagnosed Local Advanced Cervical Cancer
NCT06251388Cervical Cancer
West China Second University Hospital
Phase 2
50
Chengdu
2024-02-20
Active, closed
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
NCT06243666Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection
Xiamen University
Observational
2,188
Yancheng
2024-02-20
Active, closed
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Breast Cancer
Pfizer
Phase 1/2
71
Guangzhou, Wuhan, Xi'an
2024-02-19
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Recruiting
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
NCT07122024Helicobacter Pylori
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
414
Hangzhou
2024-02-19
By invitation
Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
NCT07162467Schizophrenia
Tianjin Anding Hospital
Observational
200
Tianjin
2024-02-19
Recruiting
Rapid and Safe Sputum Suction Method Validation
NCT06508008Sputum
Affiliated Hospital of Nantong University
Not applicable
900
Nantong
2024-02-18
Recruiting
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
NCT06276088Immunotherapy, Hyperprogression, Biomarker
Nanfang Hospital, Southern Medical University
Observational
374
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-18
Active, closed
THRIVE Improves Early Postoperative Atelectasis in Long-Time Non-Tracheal Intubation Anesthesia for Gastrointestinal Endoscopy: a Clinical Study
NCT06554678Early Postoperative Atelectasis
Northern Jiangsu People's Hospital
Not applicable
150
Yangzhou
2024-02-18
Recruiting
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
NCT06897228Solid Tumors, Adult
Shenzhen Celconta Life Science Co., Ltd.
Phase 1
18
Anyang
2024-02-18
Recruiting
Early Detection and Post-operative Monitoring of Gastric Cancer
NCT06232395Gastric Cancer
Suzhou Huhu Health & Technology Inc.
Observational
1,197
Shanghai
2024-02-18
Recruiting
A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
NCT06215495Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma, Progression-free Survival
Zhujiang Hospital
Not applicable
88
Guangzhou
2024-02-18
Recruiting
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia
NCT06585345Acute-Leukemia
The General Hospital of Western Theater Command
Phase 1/2
200
Chengdu
2024-02-18
Recruiting
Post-operative Monitoring of Gastric Cancer
NCT07026240Gastric Cancer
Suzhou Huhu Health & Technology Inc.
Observational
258
Shanghai
2024-02-18
Recruiting
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
NCT06304350Esophageal Cancer
Tongji University
Phase 2
25
Shanghai
2024-02-17
Recruiting
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
NCT06607107Hepatocellular Carcinoma Non-resectable
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
29
Guangzhou
2024-02-17
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Recruiting
Study on the Use of Traditional Chinese Medicine Diagnostic Tools to Assist in Identifying the Clinical Characteristics of Inflammatory Bowel Disease and Research on Metabolic Plastids of Tongue Coating
NCT07314151Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
China Medical University Hospital
Observational
200
2024-02-15
Recruiting
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
NCT06394011Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2024-02-15
Not yet open
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
NCT06255795Extranodal Natural Killer T Cell Lymphoma
Ruijin Hospital
Phase 3
142
Shanghai
2024-02-15
Recruiting
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
NCT06248333Epilepsy, Drug Resistant
Xuanwu Hospital, Beijing
Not applicable
33
Beijing
2024-02-14
Recruiting
Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study
NCT06250842Benzodiazepine Adverse Reaction, Depression, Anxiety, Benzodiazepine Dependence
The First Affiliated Hospital of Dalian Medical University
Observational
100
Dalian
2024-02-11
Recruiting
Carotid Atherosclerosis in Predicting Coronary Artery Disease
NCT06253962Carotid Atherosclerosis, Coronary Atheroscleroses
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2024-02-10
Not yet open
Corheart 6 LVAS Long-term Follow-up Study
NCT06267612Heart Failure
Nanjing First Hospital, Nanjing Medical University
Not applicable
30
Nanjing
2024-02-10
Not yet open
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
NCT06202313Triple Negative Breast Cancer
Shengjing Hospital
Phase 2
128
Shenyang
2024-02-10
Active, closed
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853Systemic Lupus Erythematosus, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
22
Hangzhou
2024-02-10
Active, closed
Safety and Efficacy of CD19 CAR-T/CAR-NK Cells
NCT06596057Safety and Efficacy
The Second Hospital of Shandong University
Phase EARLY_PHASE1
10
Shandong
2024-02-10
Recruiting
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
NCT06321198Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
Anhui Provincial Hospital
Not applicable
12
Hefei
2024-02-10
Not yet open
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06236997Small Cell Lung Carcinoma
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Recruiting
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NCT06211114Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2024-02-09
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Not yet open
JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases
NCT06243159Autoimmune Diseases
Shanxi Bethune Hospital
Phase EARLY_PHASE1
20
Taiyuan
2024-02-08
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
Pfizer
Phase 3
492
2024-02-08
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Active, closed
Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion
NCT06179017Mild Stroke, Acute Ischemic Stroke, Endovascular Treatment, Perfusion Imaging
Zhangzhou Municipal Hospital
Not applicable
300
Fuzhou
2024-02-07
Recruiting
Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS
NCT06143488Acute Ischemic Stroke, Mild Neurocognitive Disorder, Thrombectomy
First Affiliated Hospital of Wannan Medical College
Not applicable
264
Wuhu
2024-02-07
Recruiting
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203Higher-risk Myelodysplastic Syndromes
Akeso
Phase 2
90
Tianjin
2024-02-07
Recruiting
Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol
NCT06261801Trigeminal Herpetic Neuralgia
The Third People's Hospital of Hangzhou
Not applicable
102
Hangzhou
2024-02-07
Recruiting
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414
NCT06525168Ischemic Stroke
Chendu DIAO Nine Hong Pharmaceutical Factory
Phase 1
82
Wuhan
2024-02-06
Rows per page Showing 13501–13600 of 19052
Previous 134 135 136 137 138 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china?page=136

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.